Data completeness
0/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUDAFED 12 HOUR is an extended-release oral capsule containing a decongestant (presumed pseudoephedrine) designed to provide sustained symptom relief over 12 hours. The drug treats nasal congestion and related upper respiratory symptoms associated with colds, allergies, or sinusitis. Mechanism of action involves sympathomimetic activity to reduce nasal mucosal edema and improve airflow.
Pre-Launch
Pre-launch stage indicates active commercial planning and hiring for launch roles; team scaling expected in the coming 12–18 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SUDAFED 12 HOUR offers a launch-stage opportunity in a high-visibility OTC brand under GSK's portfolio, with exposure to consumer marketing, retail partnerships, and rapid commercialization cycles. However, limited patent protection and generic competition mean career tenure on this product may be compressed; professionals should anticipate transition planning within 2–3 years post-launch.
Brand Manager
Worked on SUDAFED 12 HOUR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.